Latest News
Solid Biosciences Inc.
- Leerink Partners Remains a Buy on Solid Biosciences (SLDB)
- Solid Biosciences presents seven studies. Solid Biosciences stock is valued at USD 686.2 million
- Solid Biosciences CMO Gabriel Brooks Vests 9,750 RSUs and Sells 4,374 Shares to Cover Taxes
- Solid Biosciences to present seven posters on Duchenne and platform advances at ESGCT2026
- Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
- A gene therapy for Duchenne, a muscle disease, is among seven posters Solid Biosciences will present.
- Form 4 Solid Biosciences LLC For: 11 October By Investing.com
- What Explains the 5.72% Premarket Gain for Solid Biosciences (NASDAQ:SLDB)?
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)
- Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB)
- Solid Biosciences is a speculative buy with pro...
Headlines from the last 30 days, linking to the original publishers. See all market news →